Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: SGLT2 inhibitors and lower limb complications: an updated meta‐analysis

Fig. 2

Meta-regression analysis for the associated factors and risk of lower limb complications in patients with SGLT2i treatment. a The association between weigh change and risk of amputation in patients with SGLT2i treatment. b The association between weigh change difference and risk of amputation in patients with SGLT2i treatment. c The association between baseline DBP and risk of amputation in patients with SGLT2i treatment. d The association between weigh change and risk of PAD in patients with SGLT2i treatment. e The association between weigh change difference and risk of PAD in patients with SGLT2i treatment. f The association between SBP change and risk of PAD in patients with SGLT2i treatment. g The association between weigh change and risk of DF in patients with SGLT2i treatment. h The association between weigh change difference and risk of DF in patients with SGLT2i treatment. i The association between DBP change and risk of DF in patients with SGLT2i treatment. DBP, diastolic blood pressure; DF, diabetic foot; PAD, peripheral arterial disease; SBP, systolic blood pressure; SGLT2i, sodium glucose co-transporter 2 inhibitor

Back to article page